Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Want to see CORT full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.03Last Year’s EPS
0.29Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by major clinical and regulatory milestones (Lifyorli FDA approval with a significant survival benefit, landmark CATALYST and MOMENTUM findings that broaden the addressable market, robust patient and prescriber growth, raised 2026 guidance, and compelling ALS and MASH data). Near-term negatives include a Q1 earnings swing to a net loss, temporary revenue headwinds from insurance reauthorizations and a pharmacy-transition backlog, and tolerability-related discontinuations in DAZALS that require mitigation. On balance, the company demonstrated durable commercial traction, an expanding pipeline with high-impact results, and clear plans to address operational issues, leading to a favorable outlook.Company Guidance
Quarterly Revenue and Raised Guidance
Revenue of $164.9 million in Q1 2026 versus $157.2 million a year earlier, an increase of approximately 4.9%. Company raised 2026 revenue guidance to $950 million–$1.05 billion.
Strong Cash Position
Cash and investments of $515 million as of March 31, 2026 providing runway for ongoing commercial and development programs.
Record Commercial Demand for Endocrinology Franchise
All-time highs in number of new prescriptions, number of prescribers and total patients receiving medications; record new patient starts in March and again in April, indicating accelerating demand.
CATALYST and MOMENTUM Clinical Findings Driving Market Expansion
CATALYST: 24% of patients with resistant diabetes had hypercortisolism; treatment with Korlym produced substantial reductions in HbA1c, weight and waist circumference (published in Diabetes Care, Dec 2025; referenced in AACE guidance Mar 2026). MOMENTUM: 27% of patients with resistant hypertension had hypercortisolism (presented at ACC). Management expects these studies to materially increase screening and treatment demand and projects Cushing's syndrome business to grow to at least $2 billion annually by decade-end.
Lifyorli FDA Approval and Compelling ROSELLA Results
FDA approved Lifyorli for platinum-resistant ovarian cancer 3.5 months ahead of PDUFA. ROSELLA pivotal trial met both primary endpoints: Lifyorli + nab-paclitaxel reduced risk of death by 35% (hazard ratio 0.65; p=0.0004). No biomarker required. Results published in The Lancet.
Rapid Commercial Launch Traction for Lifyorli
Product available within 5 days of approval; within ~36 days into launch, prescriptions written by over 200 physicians across community oncology, gynecology and academic centers; included as a preferred regimen in NCCN guidelines 15 days after approval. Management projects Lifyorli to exceed $1 billion annual U.S. revenue by decade-end.
Promising ALS and MASH Development Data
DAZALS (dazucorilant) in ALS: 300 mg showed an 84% reduction in risk of death at 1 year (p=0.0009) and 87% reduction at 2 years (p<0.0001). Company plans pivotal Phase III starting later this year with survival as primary endpoint. Miricorilant for MASH: Phase IIb MONARCH fully enrolled (175 patients) with results expected by year-end; earlier Phase Ib showed rapid liver fat reduction and fibrosis marker improvement.
Active Oncology Development Portfolio Beyond Lifyorli
Relacorilant NDA in Cushing's syndrome under FDA discussion; BELLA trial (relacorilant + nab‑paclitaxel + bevacizumab) first-arm results due by year-end. Additional relacorilant and nenocorilant studies (including Phase Ib with nivolumab) ongoing with multiple readouts planned through next year.
CORT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CORT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $46.52 | $51.42 | +10.53% |
Feb 24, 2026 | $36.48 | $36.22 | -0.71% |
Nov 04, 2025 | $71.10 | $76.65 | +7.81% |
Jul 31, 2025 | $67.17 | $69.00 | +2.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Corcept Therapeutics Inc. (CORT) report earnings?
Corcept Therapeutics Inc. (CORT) is schdueled to report earning on Aug 05, 2026, TBA (Confirmed).
What is Corcept Therapeutics Inc. (CORT) earnings time?
Corcept Therapeutics Inc. (CORT) earnings time is at Aug 05, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CORT EPS forecast?
CORT EPS forecast for the fiscal quarter 2026 (Q2) is 0.03.